JSPR – jasper therapeutics, inc. - class a (US:NASDAQ)
Stock Stats
News
Johnson Fistel, PLLP Begins Investigation on Behalf of Long-Term Shareholders of Jasper Therapeutics, Inc. (JSPR), KBR, Inc. (KBR), LifeMD, Inc. (LFMD), and Lineage, Inc. (LINE)
Jasper Therapeutics (NASDAQ:JSPR) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
Jasper Therapeutics (NASDAQ:JSPR) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating and a $17.00 price target on the stock.
Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria
Jasper Therapeutics Appoints Jeet Mahal as Chief Executive Officer to Lead Next Phase of Clinical Growth
Form SCHEDULE 13G Jasper Therapeutics, Filed by: GOLDMAN SACHS GROUP INC
Form SCHEDULE 13G Jasper Therapeutics, Filed by: MORGAN STANLEY
Form 4 Jasper Therapeutics, For: Feb 06 Filed by: Mahal Jeetinder Singh
Form SCHEDULE 13G/A Jasper Therapeutics, Filed by: ACORN BIOVENTURES, L.P.
Form 8-K Jasper Therapeutics, For: Jan 08
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.